Yonhap Infomax News15h ago
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456
Royed Training2d ago

🌍 Pharma IPR is now a strategic business function.
Learn US EU & Global Pharma Patent Strategy, Biosimilar Patent Dance, Para IV, FTO Analysis, Licensing Portfolio Management through hands-on training

📌 https://zurl.co/58m4n

#PharmaIPR #Biosimilar #PatentDance #Biologics

Yonhap Infomax NewsApr 7
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173
Celltrion's Truxima Achieves No. 1 Market Share in US

Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.

Yonhap Infomax
Yonhap Infomax NewsJan 26
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024
Samsung Bioepis Q4 Operating Profit Plunges 60% to 29.2 Billion Won

Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.

Yonhap Infomax
Yonhap Infomax NewsJan 15
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079
Samsung Bioepis Holdings to Expand New Drug Development on Biosimilar Success

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.

Yonhap Infomax
Yonhap Infomax NewsDec 16
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705
Tin hot mỗi ngàyNov 13, 2025

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi-2/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Tin hot mỗi ngàyNov 13, 2025

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Jeff Levin-Scherz MDNov 6, 2025
Today in #Employer Coverage: The US lags in savings from #biosimilar medications. New regs are a step in the right direction. https://employercoverage.substack.com/p/the-us-lags-in-savings-from-biosimilar
Yonhap Infomax NewsNov 3, 2025
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896
Celltrion Secures Additional FDA Approval for Yuflyma 10mg Formulation in US

Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.

Yonhap Infomax